Cargando…
Combination of Mesenchymal Stem Cell-Delivered Oncolytic Virus with Prodrug Activation Increases Efficacy and Safety of Colorectal Cancer Therapy
Although oncolytic viruses are currently being evaluated for cancer treatment in clinical trials, systemic administration is hindered by many factors that prevent them from reaching the tumor cells. When administered systemically, mesenchymal stem cells (MSCs) target tumors, and therefore constitute...
Autores principales: | Ho, Chun-Te, Wu, Mei-Hsuan, Chen, Ming-Jen, Lin, Shih-Pei, Yen, Yu-Ting, Hung, Shih-Chieh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8153168/ https://www.ncbi.nlm.nih.gov/pubmed/34068264 http://dx.doi.org/10.3390/biomedicines9050548 |
Ejemplares similares
-
PP2A in LepR+ mesenchymal stem cells contributes to embryonic and postnatal endochondral ossification through Runx2 dephosphorylation
por: Yen, Yu-Ting, et al.
Publicado: (2021) -
Mesenchymal Stem Cells From a Hypoxic Culture Can Improve Rotator Cuff Tear Repair
por: Chen, Hsin-Shui, et al.
Publicado: (2022) -
Oncolytic viruses: finally delivering
por: Seymour, Leonard W, et al.
Publicado: (2016) -
Paracrine Senescence of Mesenchymal Stromal Cells Involves Inflammatory Cytokines and the NF-κB Pathway
por: Chou, Lun-Yin, et al.
Publicado: (2022) -
Functional roles of pluripotency transcription factors in mesenchymal stem cells
por: Tsai, Chih-Chien, et al.
Publicado: (2012)